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arlo Vigna, MD, FESC,* Nicola Marchese, MD,* Vincenzo Inchingolo, MD,†
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atteo Impagliatelli, MD,* Rosaria Natali, MD,§ Aldo Russo, MD,* Raffaele Fanelli, MD,*
rancesco Loperfido, MD§
an Giovanni Rotondo and Rome, Italy
bjectives We sought to evaluate the beneﬁts on frequency and severity of migraine recurrence
fter patent foramen ovale (PFO) closure in patients with subclinical brain lesions at magnetic reso-
ance imaging (MRI).
ackground Migraine improvement has been reported after PFO closure in patients with cerebro-
ascular symptomatic events. Subclinical brain MRI lesions are detectable in patients with PFO and
n migraineurs.
ethods A total of 82 patients with moderate/severe migraine, PFO, large right-to-left shunt, and
ubclinical brain MRI lesions were prospectively examined for a 6-month period. Patients were sub-
ivided into closure (n  53) and control (n  29) group according to their consent to undergo
ercutaneous PFO closure. In controls, therapy for migraine was optimized. Six-month frequency
nd severity of migraine recurrence were compared with baseline.
esults The number of total attacks decreased more in the closure group (32  9 to 7  7, p 
.001) than in the control group (36  13 to 30  21, p  NS) (p  0.001). A signiﬁcant reduction
n disabling attacks was observed only in the closure group (20  12 to 2  2, p  0.001; controls:
5  12 to 12  12, p  NS). Migraine disappeared in 34% of the closure group patients and 7% of
ontrols (p  0.007); 50% reduction of attacks was reported by 87% and 21%, respectively (p 
.001). Disabling attacks disappeared in 53% of closure group patients and 7% of controls (p 
.001); 50% reduction occurred in 89% and 17%, respectively (p  0.001).
onclusions In migraineurs with a large PFO and subclinical brain MRI lesions, a signiﬁcant reduc-
ion in frequency and severity of migraine recurrence can be obtained by PFO closure when com-
ared with frequency and severity in controls. (J Am Coll Cardiol Intv 2009;2:107–13) © 2009 by
he American College of Cardiology Foundation
rom the Departments of *Cardiology, †Neurology, and ‡Radiology, Casa Sollievo della Sofferenza Hospital IRCCS, San
iovanni Rotondo, Italy; and the §Department of Cardiology, Catholic University Medical School, Rome, Italy.anuscript received September 29, 2008; accepted October 16, 2008.
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108igraine, a form of headache affecting about 10% of the adult
opulation (1), has been found to be associated with patent
oramen ovale (PFO). In fact migraineurs, and in particular
hose with aura, often show PFO (2,3); conversely, subjects
ith PFO more frequently complain of migraine than controls
2). In patients with cryptogenic stroke, percutaneous closure
f PFO is a therapeutic option but has not been approved by
he U.S. Food and Drug Administration pending results of
andomized clinical trials. Moreover, in migraineurs with prior
troke, significant reduction or even disappearance of migraine
ttacks has been consistently reported as an additional benefit
btained by PFO closure (4–13). However, it has not been
onclusively established if an invasive approach can improve
ymptoms also in “pure” migraineurs (i.e., patients without
revious clinical cerebrovascular events).
See page 114
Single or multiple brain lesions affecting the myelinated
hite matter are frequently observed at cerebral magnetic
esonance imaging (MRI) in patients with both migraine and
PFO and may represent silent
ischemic events (14–16). The aim
of the present prospective case-
control study was to determine if
percutaneous PFO closure, in
comparison to standard medical
therapy, may be beneficial for mi-
graine in the selected subset of
patients with large right-to-left
shunt (RLS), subclinical brain
MRI focal lesions, and moderate/
severe migraine.
ethods
atients. From June 2004 to October 2006, we prospec-
ively examined 156 consecutive patients60 years old with
igraine and PFO, but without cardiac, aortic, or cerebro-
ascular causes for cerebral ischemia. Among this cohort, we
elected the patients fulfilling the following criteria: 1)
oderate/severe migraine (4 monthly attacks) with or
ithout aura; 2) PFO with significant spontaneous or
nducible large RLS as demonstrated by contrast transcra-
ial color Doppler (TCCD); and 3) MRI evidence of single
r multiple brain lesions. Patients with previous symptom-
tic episodes of cerebral ischemia (stroke or transient isch-
mic attack) were excluded. Other exclusion criteria were
eurodegenerative, psychiatric, inflammatory, or infective
iseases, pregnancy, contraindication to antiplatelet therapy,
nd chronic use of preventive medications against migraine.
The resulting group consisted of 82 patients (74 females,
ge 43  10 years) that were clinically examined at our
bbreviations
nd Acronyms
ES  microembolic signals
RI  magnetic resonance
maging
FO  patent foramen ovale
LS  right-to-left shunt
CCD  contrast
ranscranial color Doppler
M  Valsalva maneuvererebrovascular Disease Unit for a 6-month evaluation seriod. In all patients, clinical history was carefully col-
ected, including cardiovascular risk factors and current
edical treatment. Moreover, all patients had a complete
aboratory screening for thrombophilia (antithrombin III,
nticardiolipin, and antiphospholipid antibodies; lupus an-
icoagulant; levels of protein C and free protein S; homo-
ysteine; and genetic tests for factor V Leiden and factor II).
hrombophilia was stated in the presence of abnormalities
n1 of these tests. This study received the approval by our
nstitutional Review Board Committee and all patients gave
written informed consent to participate.
ssessment of migraine. Migraine was evaluated by an
xperienced neurologist (V.I.), blinded to the protocol, in
ccordance with the International Headache Society criteria
17). Number and characteristics of migraine attacks were
ssessed during the 6-month evaluation period. Patients
ompleted a detailed questionnaire where they reported
requency and severity of migraine. In particular, they
ndicated duration of attacks (time from onset until termi-
ation of an attack of headache, with or without symptom-
tic therapy), intensity of pain (according to a 4-point scale:
 no pain; 1  mild pain, not interfering with usual
ctivities; 2  moderate pain, inhibiting but not completely
reventing usual activities; 3  severe pain, preventing all
ctivities), occurrence of aura or accompanying symptoms
e.g., nausea, vomiting, photophobia, phonophobia), and
esponse to symptomatic therapy.
We considered disabling the attacks with a duration
reater than 6 h, associated with severe pain, not allowing
ny activity, with multiple accompanying symptoms and
oor response to symptomatic pharmacological therapy (no
hange in the intensity scale).
ransthoracic and transesophageal echocardiography, TCCD.
transthoracic echocardiography was accomplished as a
rst-line examination. The diagnosis and subsequent ana-
omical and functional evaluation of PFO were performed
y TCCD and transesophageal echocardiography with an
TL HDI 5000 system (ATL Ultrasound Inc., Bothell,
ashington) at the time of recruitment. We achieved
CDD according to the recommendations of the Venice
onsensus Conference (18). On the basis of microembolic
ignals (MES) count, we adopted a previously described
-level scale for classification of shunt (19): 0  absence of
hunt (0 MES); 1  latent shunt of mild degree (1 to 20
ES) after Valsalva maneuver (VM); 2  latent shunt of
oderate degree (20 MES after VM, without curtain);
 latent shunt of high degree (curtain after VM); 4 
ermanent shunt of mild/moderate degree (10 MES at
est and curtain after VM); 5  permanent shunt of high
egree (curtain at rest).
All patients recruited had a large RLS (at least grade 3 at
CCD). Transesophageal echocardiography was performed
ith a 5-MHz phased multiplane probe. In addition totandard views, we studied the fossa ovalis region to detect
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109separation between septum primum and secundum. The
riteria for atrial septal aneurysm were a diameter of the base
15 mm and a total excursion of the septum 10 mm
19,20). We qualitatively defined RLS at transesophageal
chocardiography as the passage in left atrium of the same
ontrast agent used for TCCD studies (10 ml administered
ntravenously) within 3 cycles from the appearance in the
ight atrium at rest and, if negative, at the end of VM.
rain MRI. We performed MRI using a 3-T system (GE
ealthcare, Milwaukee, Wisconsin) according to an imag-
ng protocol including: 1) a diffusion-weighted single-shot
pin echo echo-planar sequence acquired in the anterior
ommissure–posterior commissure plane with 24 contigu-
us sections (diffusion gradient b values of 0 and 1,000
/mm2, repetition time: 6,000 ms, echo time: 120 ms, slice
hickness: 6 mm with no gap, matrix of 128  128 pixels,
nd field of view of 240 mm); 2) fluid-attenuated inversion
ecovery (repetition time/echo time: 10,000/160 ms; inver-
ion time: 2,200 ms); and 3) T2-weighted turbo spin echo
equences (repetition time/echo time: 3,500/94 ms). For
iffusion sequence, gradients were successively and sepa-
ately applied in 6 orthogonal directions for a total acquisi-
ion time of 24 s. Trace images were then generated and
pparent diffusion coefficient maps calculated with a dedi-
ated software tool (Functool, GE Healthcare). The MRI
tudies were analyzed by 2 independent expert observers
ho were blinded to the clinical data. A consensus was
chieved in case of disagreement. All patients enrolled had
MRI positive for white matter abnormalities defined
ccording to other studies (14).
ubdivision of patients. At the end of the 6-month evalu-
tion period, PFO closure was proposed for prevention of
hite matter lesions progression or thromboembolism. All
atients were informed about clinical benefits and risks of
FO closure but not about possible effects on migraine.
ifty-three patients accepted to undergo the procedure
closure group), and 29 patients, who refused the PFO
losure, constituted the control group. Medical therapy was
e-evaluated in controls by a neurologist blinded to the
rotocol and, if necessary, a preventive drug for migraine
as introduced, whereas patients in the closure group were
llowed to take only symptomatic drugs during migraine
ttacks.
Percutaneous closure of PFO was performed under local
nesthesia with intracardiac ultrasound guidance (9-MHz
ltraICE, Boston Scientific Corporation, San Jose, Cali-
ornia) to optimize the placement of the devices. The PFO
ccluder was Amplatzer in 35 (66%), fourth-generation
ardia in 10 (19%), and Cardioseal/STARflex in 8 (15%)
atients. Afterward, patients received double antiplatelet
herapy with aspirin (100 mg/day) and clopidogrel (75
g/day) for 3 months and subsequently aspirin alone for 3
onths. gollow-up. Patients in the closure group underwent a com-
lete transthoracic echocardiographic examination the day
fter the procedure and TCCD at 3, 6, 12 months and then
very 12 months to evaluate a possible residual RLS.
oreover, transesophageal echocardiography was per-
ormed at 6 months. All patients were followed up for the
ccurrence of death, recurrent ischemic stroke, transient
schemic attack, or peripheral embolism. In the case of
uspected recurrent cerebrovascular event, a new neurolog-
cal examination, including brain MRI, was scheduled.
Follow-up of migraine started 6 months after the invasive
rocedure in the closure group and 6 months after optimi-
ation of therapy in controls. Frequency and severity of
igraine were again assessed for 6 months, similarly as for
he evaluation period. In comparison with baseline, 50%
ecrease in the number of total and disabling attacks was
onsidered to be a significant clinical improvement for
requency and severity of migraine recurrence, respectively.
ata analysis. Data are reported as mean  standard
eviations. We used the Fisher exact test for categorical
ariables and the t test or Mann-Whitney U test for scale
ariables if data followed normal or non-normal distribu-
ion, respectively. Frequency of migraine at baseline and
fter treatment was compared by a Wilcoxon signed rank
est. A propensity score, reflecting the probability to un-
ergo percutaneous closure of PFO, was derived, including
ge, sex, presence of aura, septal aneurysm, thrombophilia,
umber of total and disabling attacks, and entity of RLS in
he model. The goodness of fit was given by the area under
eceiver-operating characteristic curve being 0.89. The pro-
ensity score was incorporated into a logistic regression to
djust the estimate of the treatment effect on migraine. The
evel of significance for all tests was fixed at p  0.05
2-tailed). Statistical analysis was performed with Statistical
ackage for Social Sciences software (SPSS 11.0 for Win-
ows, SPSS, Chicago, Illinois).
esults
aseline characteristics and in-hospital post-procedural
vents. Patients in the closure group and controls did not
iffer significantly in baseline characteristics, including the
revalence of thrombogenic factors (Table 1). In the eval-
ation period, the total number of migraine attacks was
imilar in the 2 groups of patients (32  9 vs. 36  13, p 
S) but disabling attacks were more frequent in patients
ubsequently undergoing PFO closure (20  12 vs. 15 
2, p  0.012). We did not register any major acute clinical
vent (in-hospital deaths or systemic thromboembolic
vents) after PFO closure.
ollow-up. The mean duration of follow-up was 16  7
onths (range: 12 to 25 months), and no cardiovascular
vents occurred. At 3- and 6-month TCCD in the closure
roup, we found a residual grade 2 RLS in 1 patient and a
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110rade 1 RLS in 2 patients. These results were confirmed at
-month transesophageal echocardiography and 1-year
CCD. Nine controls (31%) received preventive therapy for
igraine after the evaluation period.
At 6-month follow-up, patients in both the closure and
ontrol groups reported a significant reduction in the
umber of migraine attacks (closure group: from 32  9 to
 7, p  0.001; controls: from 36  13 to 30  21, p 
Table 1. Baseline Characteristics
PFO Closure Group
(n  53)
Control Group
(n  29)
Age, yrs 42  10 43  11
Sex, male/female 5 (9%) / 48 (91%) 3 (10%) / 26 (90%)
1 cardiovascular risk factors 2 (4%) 1 (3%)
Hormone replacement therapy 9 (17%) 5 (17%)
Presence of aura 23 (43%) 13 (45%)
Thrombophilia, % 15 (28) 8 (28%)
Grading of RLS at TCCD 3.4 0.6 3.3 0.6
Grade 3 33 (62%) 23 (79%)
Grade 4 16 (30%) 4 (14%)
Grade 5 4 (8%) 2 (7%)
Septal aneurysm 17 (32%) 10 (34%)
Values are mean  standard deviation or n (%). Differences between the closure group and
control groupwere not statistically significant (p 0.05). Thrombophilia were stated if1 of the
subsequent thrombogenic risk factors were positive: polymorphism of factor V Leiden, polymor-
phismof factor II, lupuslike anticoagulant, anticardiolipin antibodies, protein C antigen, protein S,
antithrombin, hyperhomocysteinemia. Grades are explained in the Methods. Septal aneurysm:
diameter of the base15 mm and total excursion of the septum10 mm.
PFO patent foramen ovale; RLS right-to-left shunt; TCCD transcranial color Doppler.
Figure 1. Frequency of Migraine Attacks at Baseline and Follow-Up
A signiﬁcant reduction in frequency of total attacks was observed in the 2 gro
improvement (patent foramen ovale closure group vs. controls: p  0.001). Ea
repeated measures statistic analysis. MT  optimized medical therapy..038), but the reduction was greater in the first group (p 
.001) (Fig. 1). Migraine completely disappeared in 34% of
FO closure patients and 7% of controls (p 0.007) (Table
). A significant improvement in frequency of migraine
ecurrence was registered in 87% and 21% of them, respec-
ively (p  0.001) (Table 2).
At 6-month follow-up, only patients in the closure group
eported a significant decline in the number of disabling
owever, patients in the closure group exhibited a greater symptomatic
e represents 1 patient. *6-month evaluation period versus 6-month follow-up,
Table 2. Clinical Results According to Treatment Allocation
PFO Closure Group
(n  53)
Control Group
(n  29)
p
Value
Aura NS
Pre 23 (43%) 13 (45%)
Post 10 (19%) 9 (31%)
Total attacks
∆ (pre–post) 25  13 6  13 0.001
Disappearance 18 (34%) 2 (7%) 0.007
50% reduction 46 (87%) 6 (21%) 0.001
Disabling attacks
∆ (pre–post) 18  13 2  7 0.001
Disappearance 28 (53%) 2 (7%) 0.001
50% reduction 47 (89%) 5 (17%) 0.001
Values aremean standard deviation or n (%). A greater reduction of total and disabling attacks
was observed in the closure group compared with the control group (p  0.001). Similarly,
patients in the closure group reported a greater benefit in frequency and severity of migraine
recurrence than patients in the control group.
NS nonsignificant; pre episodes in the 6-month evaluation period; post episodes in the
6-month follow-up;  (pre–post) difference between the number of attacks in the evaluation
period and in follow-up; other abbreviation as in Table 1.ups. H
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111ttacks (from 20  12 to 2  2, p  0.001; controls: from
5  12 to 12  12, p  NS; p  0.001 between the 2
roups) (Fig. 2). Disabling attacks disappeared in 53% of
FO closure patients and 7% of controls (p 0.001) (Table
). Significant clinical improvement in severity of migraine
as registered in 89% and 17% of them, respectively (p 
.001) (Table 2). No significant differences in aura reduc-
ion were observed between the 2 groups (Table 2). In
ddition, the degree of improvement in frequency and
everity of migraine recurrence after PFO closure was
imilar in patients with and without aura.
In the patient with residual grade 2 RLS (grade 4 before
FO closure), we observed a small (50%) decrease in total
from 28 to 19) and disabling (from 10 to 8) attacks. As
egards the 2 patients with residual grade 1 RLS (grade 3 at
aseline), 1 exhibited a little decrease in total attacks (from
8 to 20) and unchanged frequency of disabling attacks (n
5), and the other reported a clinically significant symptom-
tic benefit.
After adjustment for propensity score, the significant
dvantage for patients in the closure group persisted in
erms of migraine disappearance (odds ratio [OR]: 6.9, 95%
onfidence intervals [CI]: 1.5 to 32.5, p  0.014), disap-
earance of disabling attacks (OR: 15, 95% CI: 3.2 to 70,
 0.001), improvement in frequency (OR: 25.2, 95% CI:
.6 to 83.6, p  0.001), and severity of migraine attack
Figure 2. Frequency of Disabling Attacks at Baseline and Follow-Up
Frequency of disabling migraine was reduced signiﬁcantly only in closure grou
sents 1 patient. *6 month evaluation period versus 6-month follow-up, repeateecurrence (OR: 37.6, 95% CI: 10.4 to 135.8, p  0.001). miscussion
igraine, a disorder with important socioeconomical im-
act, is very frequent in the Caucasian population (1).
everal studies have highlighted the association between
igraine and PFO. In a large study recruiting 334 mi-
raineurs (21), prevalence of PFO has been found to be
ouble when compared with PFO in the general population,
nd particularly high in the presence of aura (21). Similarly,
igraine has been reported to be highly prevalent (up to
6%) in patients with PFO (22). A possible beneficial effect
f PFO closure on migraine has been suggested by several
oth retrospective (4,6–10,12,13) and prospective studies
5,11). Many previous studies, however, were not controlled
4–8,12,13); moreover, migraineurs were selected from
tudy populations with a previous cryptogenic stroke, and a
ossible confounding effect from antiplatelet therapy on
igraine was not always considered. Finally, when retro-
pective, these studies were exposed to a referral bias risk.
The typical patient enrolled in most of these studies had
uffered from cerebrovascular events (stroke or transient
schemic attack), presumably caused by paradoxical throm-
oembolism, and complained of migraine of whatsoever
everity. In this setting, migraine disappeared after PFO
losure in a large percentage of patients, up to 80% (7).
owever, a recent systematic review including 6 studies and
94 migraineurs, although confirming the improvement in
tent foramen ovale closure group vs. controls: p  0.0001). Each line repre-
asures statistic analysis. Abbreviations as in Figure 1.p (paigraine symptoms after PFO closure, also showed a very
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112ow grade of evidence (2). Moreover, the recently published
rospective, randomized, and sham-controlled MIST (Mi-
raine Intervention with STARFlex Technology) trial, fo-
used on a different clinical setting (moderate or large RLS
onsistent with PFO, migraine but no prior cerebrovascular
vents), failed to support a significant advantage of PFO
losure in comparison with medical treatment (23). How-
ver, inherent methodological limitations have been out-
ined (24–26), as the use of contrast transthoracic echocar-
iography to detect PFO and quantify RLS.
The present prospective case-control study enrolled pa-
ients with an intermediate cluster of characteristics com-
ared with previous uncontrolled studies and MIST trial. In
act, we rigorously selected patients with large RLS, mod-
rate/severe migraine and no previous symptomatic cerebro-
ascular events, but with brain MRI lesions presumably due
o silent ischemic episodes. Thus, our patients with high-
rade RLS (associated with migraine and stroke) (22) and
oderate/severe migraine had the room for significant
mprovement in frequency and severity of symptoms. More-
ver, these patients probably constituted a group at high risk
or future cerebrovascular events. In fact, multiple silent
rain lesions, especially in the posterior cerebral circulation,
ave been detected in patients with cryptogenic stroke and
large PFO (15,16). Also, “pure” migraineurs exhibit a high
requency of unexplained brain abnormalities, and a causal
ink with PFO can be suggested, although an imbalance of
xygen support and consumption during migraine cannot be
xcluded (14). A PFO closure may then result in symptom-
Figure 3. Clinical Results in PFO Closure Group and in Controls
Clinical results at 6-month follow-up compared with the 6-month evaluation p
age and the absolute number of patients in every clinical subgroup. PFO  patic relief of migraine through prevention of paradoxical ticroembolism or direct passage of vasoactive substances
ot filtered by the lungs (24).
In our study, patients treated with PFO closure signifi-
antly improved in frequency and severity of migraine
ecurrence. Although mild improvement was reported by
ome patients treated conservatively, most of them did not
how a significant benefit and about one-third of them did
ot improve or even worsened (Fig. 3). Most importantly,
nly patients in the closure group reported a significant
eduction of migraine severity (i.e., decrease in disabling
ttacks), which is crucial for quality of life. In contrast, the
umber of disabling attacks did not change or increased in
1% of controls (Fig. 3). Finally, in contrast to Azarbal et al.
9), we did not observe any influence of associated aura on
linical results after PFO closure.
Some methodological strengths of our study should be
mphasized: PFO and RLS were carefully assessed by both
CCD and transesophageal echocardiography; a possible
onfounding effect of antiplatelet drugs was minimized by
tarting the follow-up 6 months after treatment allocation,
lthough an effect limited to the first days after discontin-
ation cannot be excluded; we considered both frequency
i.e., total attacks number) and severity (i.e., disabling
ttacks number) of migraine recurrence, avoiding the com-
lexities of a severity score; finally, the use of intracardiac
ltrasound optimized the accuracy of well-sized devices and
esulted in few residual RLS.
tudy limitations. Some study limitations need to be recog-
ized. Patients were not randomized but simply allocated to
according to treatment allocation. Values next to bars refer to the percent-
oramen ovale.eriodreatment on the basis of their consent, which may have
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113een influenced by personal knowledge of the link between
FO and migraine. The higher number of disabling attacks
uring the evaluation period in closure group than in
ontrols may have overemphasized the clinical benefit in the
rst group. The medical therapy was not standardized. Our
tudy population was relatively small, although larger than
n most comparable studies. Finally, frequency and charac-
eristics of migraine were self reported, and different forms
f headache could not have been definitively excluded.
onclusions
significant reduction in frequency and severity of migraine
ecurrence can be obtained by PFO closure in patients with
arge RLS and without previous symptomatic cerebrovascu-
ar events, but with silent brain lesions at MRI. However, a
arger randomized trial, focused on this setting of patients
ith PFO, is necessary to confirm our results.
eprint requests and correspondence: Dr. Carlo Vigna, Depart-
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